5 results
To demonstrate that the small dose of Picoprep (2 times 150 ml with 3-4 litres of clear fluids) is as efficacious for bowel cleansing as small dose Moviprep (PEG) (2 litre with 2 litres of clear fluids) and that Picoprep is as safe as Moviprep and…
The objective of this study is to evaluate the effects of sotatercept treatment (plus maximum tolerated background PAH therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first event of all cause death, lung…
Objective 1: Compare the predictions of the EzaPredictive 1.0 ML models for hospital admission, ER LOS, and hospital LOS with healthcare professional predictions. Objective 2: Assess healthcare professional experience and acceptance of EzaPredictive…
This study will assess the safety and tolerability of sotatercept in pediatric participants with PAH WHO Group 1 who receive PAH background therapy. In the absence of treatment, the majority of patients succumb to heart failure within a few years of…
Primary:The primary objective of this open-label, LTFU study is to evaluate the long-term safety and tolerability of sotatercept when added to background PAH therapy in adult participants with PAH.Secondary:The secondary objective is to follow…